Analysis of prognostic factors and the related factors on subtype transformation of ret-roperitoneal liposarcoma
10.3969/j.issn.1000-8179.2016.08.310
- VernacularTitle:腹膜后脂肪肉瘤亚型转换的相关因素及预后分析
- Author:
Mingke HUO
;
Guangsen HAN
;
Yuzhou ZHAO
;
Pengfei MA
;
Yajie ZHENG
;
Zengci RUN
- Publication Type:Journal Article
- Keywords:
retroperitoneal liposarcoma;
multi-visceral resection;
subtype transformation;
prognosis
- From:
Chinese Journal of Clinical Oncology
2016;43(8):334-338
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To retrospectively analyze related factors of subtype transformation and to identify prognostic factors for pa-tients with retroperitoneal liposarcoma (RPLS). Methods:This study retrospectively analyzed the clinical data of 92 patients with RPLS, which were confirmed by postoperative pathology from July 1997 to October 2014 in Henan Provincial Tumor Hospital. Related studies were reviewed, and the prognoses were followed up. The factors may affect subtype transformation or prognoses were applied to the statistical analysis. Results:A total of 74 patients with RPLS were included according to the recruiting standard. The 5-year survival rate was 48.65%. Lobulated tumors (P=0.013) were the correlative factors that influenced subtype transformation. The Log-rank test showed that the age at diagnosis (P=0.045), multi-visceral resection (P=0.042), tumor necrosis (P<0.001), subtype transformation (P<0.001), and malignant level of pathological subtypes of the first operation (P<0.001) influenced overall survival. Multivariate Cox re-gression analysis showed that tumor necrosis and the malignant level of the initial histological grade were independent factors of over-all survival. Conclusion:Lobulated tumors are likely to transform the subtype. The prognosis of patients with RPLS is correlated with multi-visceral resection, tumors necrosis, subtype transformation, and the malignant level of pathological subtypes of the first opera-tion. Multi-visceral resection could not improve the 5-year survival rate of RPLS, and adjuvant therapy could not improve the prognosis.
